VectorY Therapeutics

About VectorY Therapeutics

VectorY Therapeutics is pioneering vectorized antibody therapies aimed at reversing the course of neurodegenerative diseases, with a mission to bring hope to diagnoses through innovative treatments.

Products & Services

VTx-002 and VTx-001 for ALS:Vectorized antibody treatments targeting Amyotrophic Lateral Sclerosis (ALS) as part of their pipeline for neurodegenerative diseases.

VTx-003 for Huntington's:A vectorized antibody treatment focused on Huntington's disease, included in their neurodegenerative disease pipeline.

Vectorized Antibody Platform:A unique platform combining intracellular antibodies, AAV capsids, and manufacturing knowhow to develop treatments for neurodegenerative diseases.

Specialties

Vectorized Antibody Therapies Neurodegenerative Diseases ALS Treatment Huntington's Disease Treatment Parkinson's Disease Research AAV Capsid Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 138030000 MR: - FA: €129 million FAN: 138030000	D: 2023-11-13 FD: 2023-11-13	8 investors
2	RT: Series A T: - FT: Series A	A: 138000000 MR: - FA: €129 million ($138 million) FAN: 138000000	D: 2023-11-13 FD: 2023-11-13	8 investors

Series A Latest

2023-11-13

$138.0M

8 investors (Pro only)

Series A 2023-11-13

$138.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jim Scibetta

Chief Executive Officer

S

Sander van Deventer

President of R&D

O

Olga Uspenskaya-Cadoz

Chief Medical Officer

J

Jessica Atkinson

Chief Business Officer

B

Barbara Sanders

Chief Technology Officer

A

Adam Rosenberg

Chair of the Board of Directors

View 16 more team members with Pro

Unlock Full Team Directory

Recent News